NeurologyLive® Friday 5 — June 3, 2022

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Inaugural Class of Giants of Multiple Sclerosis Announced

The first annual awards ceremony for the Giants of Multiple Sclerosis was held during the Consortium of Multiple Sclerosis Centers Annual Meeting in National Harbor, Maryland, with winners announced in 9 categories plus 2 additional awards.

2: Pilot Study Highlights Outcome Preferences for Adolescents With Chronic Migraine, Their Parents

More than 60% of adolescents felt that it was more important to measure decreases in the frequency and intensity of headaches in terms of severe headaches/spikes rather than total headache days.

3: NeuroVoices: Michael Sughrue, MD, on Using Machine Learning to Build a Better Brain Map

The founder and chief medical officer of Omniscient Neurotechnology discussed how the use of machine learning and big data will be critical in revolutionizing our understanding of the brain and mental illnesses.

4: Raising Awareness for World MS Day, Challenges of Multiple Sclerosis

Emily Harrington, MD, PhD, a physician-scientist at The Ohio State University Wexner Medical Center, provided thoughts on the importance of World MS Day and the issues that plague the MS community.

5: FDA Approves Risdiplam to Treat Presymptomatic Babies Under 2 Months With SMA

Data from the RAINBOWFISH study and a large-scale extension, FIREFISH, were the basis for the expanded indication for risdiplam (Evrysdi; Genentech), which now includes babies with SMA under 2 months old.

—————————————————